5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.

doi:10.1016/0006-2952(94)90092-2

Paper

DOI: 10.1016/0006-2952(94)90092-2

5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs.

Published Jul 19, 1994 · S. T. Davis, S. Joyner, D. Baccanari

Biochemical pharmacology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

5-Ethynyluracil protects dogs from neurotoxicity caused by 5-fluorouracil-induced catabolism, enabling higher doses without causing gastrointestinal disturbances.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1016/0006-2952(93)90615-4

5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.

5-Ethynyluracil effectively inactivates dihydropyrimidine dehydrogenase in vivo, with a detection limit of 6 nM in human plasma and no effect from high uracil concentrations.

1993·100citations·Thomas Spector et al.·Biochemical pharmacology

Biochemical pharmacology

DOI: 10.1073/PNAS.90.23.11064

5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.

5-EU effectively modulates 5-fluorouracil catabolism, increasing its pharmacokinetics and antitumor efficacy, potentially increasing its therapeutic index by 2- to 4-fold.

1993·128citations·D. Baccanari et al.·Proceedings of the National Academy of Sciences of the United States of America

Proceedings of the National Academy of Sciences of the United States of America

DOI: 10.1016/s0021-9258(18)42757-3

Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil.

5-ethynyluracil effectively inactivates dihydropyrimidine dehydrogenase, while 5-cyanouracil is a reversible inhibitor, allowing enzyme to slowly regain activity.

1992·109citations·David J. T. Porter et al.·The Journal of biological chemistry

The Journal of biological chemistry

DOI: 10.1111/j.1440-1827.1988.tb02277.x

SUBACUTE NEUROTOXICITY OF 5‐FLUOROURACIL and ITS DERIVATIVE, CARMOFUR, IN CATS

5'-fluorouracil and its derivative carmofur cause subacute neurotoxicity in cats, causing vacuolation and softening-like changes in the brain stem, with vacuolation due to direct toxic effects on myelin and softening due to local circulatory disturbances.

1988·21citations·R. Okeda et al.·Pathology International

Pathology International

DOI: 10.1200/JCO.1987.5.10.1559

A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

5-fluorouracil and high-dose leucovorin show the best response rate and toxicity profile in previously untreated colorectal carcinoma patients, with no significant difference in survival time between the three treatment regimens.

1987·410citations·N. Petrelli et al.·Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Citations

DOI: 10.1021/acsptsci.2c00117

Dihydropyrimidine Dehydrogenase-Mediated Resistance to 5-Fluorouracil: Mechanistic Investigation and Solution.

DPD-mediated resistance to 5-fluorouracil is a major issue in cancer treatment, and strategies like analogues, downregulators, inhibitors, and formulations loaded with 5-FU can help overcome this issue.

2022·10citations·H. Verma et al.·ACS pharmacology & translational science

ACS pharmacology & translational science

DOI: 10.1016/J.CRITREVONC.2005.03.009

Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy.

In vivo (19)F magnetic resonance spectroscopy can effectively monitor fluoropyrimidine metabolism in solid tumors, potentially aiding in individualized anticancer therapy and drug development.

2005·31citations·H. V. van Laarhoven et al.·Critical reviews in oncology/hematology

Critical reviews in oncology/hematology

DOI: 10.1097/00001813-200411000-00006

Lack of contribution of dihydrofluorouracil and &agr;-fluoro-&bgr;-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes

Capecitabine's hand-foot syndrome is not primarily caused by 5-fluorouracil metabolites, but rather by high thymidine phosphorylase activity in human keratinocytes.

2004·22citations·J. Fischel et al.·Anti-Cancer Drugs

Anti-Cancer Drugs

DOI: 10.1097/00001813-200409000-00005

Peripheral neuropathy associated with capecitabine

Peripheral neuropathy with capecitabine is rare, but neurotoxicity occurs most often with intermittent high doses, likely due to 5-FU or its active metabolites.

2004·49citations·M. Saif et al.·Anti-Cancer Drugs

Anti-Cancer Drugs

DOI: 10.1007/s10147-003-0319-7

5-Fluorouracil and dihydropyrimidine dehydrogenase

DPD plays a crucial role in the pharmacokinetics of 5-fluorouracil, determining its toxicity and sensitivity in cancer chemotherapy, and drugs that control DPD activity can reduce toxicity and improve sensitivity.

2003·40citations·T. Kubota·International Journal of Clinical Oncology

International Journal of Clinical Oncology